This study is looking at basal cell carcinoma, which is a type of skin cancer that has grown locally in one area of the body but has not spread to other parts. The study will test three different treatment approaches using medications called Darleukin (also known by its code name L19IL2) and Fibromun (also known by its code name L19TNF). These medications will be given either alone or in combination with each other. The treatments will be injected directly into the skin tumor, which is called intralesional injection, meaning the medication is placed right into the affected area rather than given through the bloodstream.

The purpose of this study is to find out how well these treatments work for people with this type of skin cancer who cannot have surgery or radiation therapy, or who have chosen not to have these treatments. The study will compare the different treatment options to see which one is most effective. People taking part in this study will have a skin cancer that has either come back after previous surgeries or is in a location where surgery would cause significant problems or changes to appearance.

During the study, participants will receive injections of one of the study medications directly into their skin tumor over a period of several weeks. The study team will monitor how the tumor responds to treatment and will check for any side effects. The treatments are given in cycles, and participants will be followed to see how well the medication works at controlling or shrinking the cancer. The study is designed to help doctors understand whether these new treatment options could be helpful for people with this type of skin cancer who need alternatives to surgery or radiation.